CN113423724A - Ebv表位高亲和力t细胞受体 - Google Patents
Ebv表位高亲和力t细胞受体 Download PDFInfo
- Publication number
- CN113423724A CN113423724A CN201880099907.4A CN201880099907A CN113423724A CN 113423724 A CN113423724 A CN 113423724A CN 201880099907 A CN201880099907 A CN 201880099907A CN 113423724 A CN113423724 A CN 113423724A
- Authority
- CN
- China
- Prior art keywords
- chain
- cell
- nucleic acid
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title claims abstract description 43
- 108091008874 T cell receptors Proteins 0.000 title claims abstract description 42
- 210000004027 cell Anatomy 0.000 claims abstract description 78
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 52
- 102000036639 antigens Human genes 0.000 claims abstract description 48
- 108091007433 antigens Proteins 0.000 claims abstract description 48
- 239000000427 antigen Substances 0.000 claims abstract description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 27
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 15
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 14
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 14
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 3
- 230000036210 malignancy Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 50
- 229920001184 polypeptide Polymers 0.000 abstract description 49
- 102100037850 Interferon gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000007664 blowing Methods 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000012146 running buffer Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000012795 verification Methods 0.000 description 6
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 5
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001502 supplementing effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 229920001917 Ficoll Polymers 0.000 description 3
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101800001494 Protease 2A Proteins 0.000 description 2
- 101800001066 Protein 2A Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101000782621 Bacillus subtilis (strain 168) Biotin carboxylase 2 Proteins 0.000 description 1
- 102100025359 Barttin Human genes 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 101150059079 EBNA1 gene Proteins 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000757692 Homo sapiens ADP-ribosylation factor-like protein 2-binding protein Proteins 0.000 description 1
- 101000934823 Homo sapiens Barttin Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- -1 IFN-y Substances 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 101150113776 LMP1 gene Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种EBV表位高亲和力T细胞受体。本发明所提供的EBV表位高亲和力T细胞受体包含α链和β链；所述α链包含三个互补决定区，序列分别为SEQ ID No.3的第43‑49位、第67‑71位以及第106‑116位；所述β链包含三个互补决定区，氨基酸序列分别为SEQ ID No.4的第46‑50位、第68‑73位以及第111‑118位。本发明所提供的表达TCR的T细胞可以有效的识别T2细胞负载的EBV抗原多肽，并分泌IFN‑γ，证明其具有功能。本发明提供的EBV表位高亲和力T细胞受体具有重要的应用价值。
Description
PCT国内申请，说明书已公开。
Claims (1)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/124294 WO2020133050A1 (zh) | 2018-12-27 | 2018-12-27 | Ebv表位高亲和力t细胞受体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113423724A true CN113423724A (zh) | 2021-09-21 |
| CN113423724B CN113423724B (zh) | 2023-11-24 |
Family
ID=71126107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880099907.4A Active CN113423724B (zh) | 2018-12-27 | 2018-12-27 | Ebv表位高亲和力t细胞受体 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN113423724B (zh) |
| WO (1) | WO2020133050A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112940109B (zh) * | 2021-03-19 | 2022-03-01 | 河南省肿瘤医院 | 识别ebv抗原的t细胞受体及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102695717A (zh) * | 2009-09-29 | 2012-09-26 | Ucl商务股份有限公司 | T细胞受体 |
| WO2016095783A1 (zh) * | 2014-12-17 | 2016-06-23 | 中国科学院广州生物医药与健康研究院 | 识别eb病毒短肽的t细胞受体 |
| CN106414482A (zh) * | 2013-08-12 | 2017-02-15 | 英美偌科有限公司 | T细胞受体 |
| WO2017085471A1 (en) * | 2015-11-16 | 2017-05-26 | Cancer Research Technology Ltd | T-cell receptor and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193299A1 (en) * | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
| CN108289950B (zh) * | 2015-06-09 | 2022-10-21 | 纪念斯隆凯特琳癌症中心 | 特异于人hla呈递的ebv潜伏膜蛋白2a肽的t细胞受体样抗体药剂 |
| CN109081867B (zh) * | 2017-06-13 | 2021-05-28 | 北京大学 | 癌症特异性tcr及其分析技术和应用 |
-
2018
- 2018-12-27 CN CN201880099907.4A patent/CN113423724B/zh active Active
- 2018-12-27 WO PCT/CN2018/124294 patent/WO2020133050A1/zh active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102695717A (zh) * | 2009-09-29 | 2012-09-26 | Ucl商务股份有限公司 | T细胞受体 |
| CN106414482A (zh) * | 2013-08-12 | 2017-02-15 | 英美偌科有限公司 | T细胞受体 |
| WO2016095783A1 (zh) * | 2014-12-17 | 2016-06-23 | 中国科学院广州生物医药与健康研究院 | 识别eb病毒短肽的t细胞受体 |
| WO2017085471A1 (en) * | 2015-11-16 | 2017-05-26 | Cancer Research Technology Ltd | T-cell receptor and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113423724B (zh) | 2023-11-24 |
| WO2020133050A1 (zh) | 2020-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108409840B (zh) | 抗cd123单链抗体及其组合的嵌合抗原受体和应用 | |
| WO2018223600A1 (zh) | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 | |
| WO2018223601A1 (zh) | 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体 | |
| WO2018218877A1 (zh) | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 | |
| CN105950664B (zh) | 一种靶向cd123的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 | |
| CN105949316B (zh) | 抗EGFRvIII嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 | |
| CN112552404B (zh) | 一种靶向c-Met的单链抗体、嵌合抗原受体、重组载体、CAR-T细胞及应用 | |
| CN105820254B (zh) | 抗cd138嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 | |
| WO2018218879A1 (zh) | 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用 | |
| CN112251412B (zh) | 一种靶向bcma的嵌合抗原受体t细胞及其应用 | |
| CN113122503A (zh) | 一种靶向t细胞淋巴瘤细胞的通用型car-t及其制备方法和应用 | |
| CN114230658A (zh) | 新型冠状病毒特异性t细胞受体和其用途 | |
| CN105950662B (zh) | 一种靶向cd22的复制缺陷性重组慢病毒car-t转基因载体及其构建方法和应用 | |
| CN112940108B (zh) | 识别ebv抗原的t细胞受体以及该t细胞受体的应用 | |
| CN107098981B (zh) | 一种靶向cd19的嵌合抗原受体修饰的t淋巴细胞 | |
| CN107286246B (zh) | 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法 | |
| CN112940105B (zh) | HLA-A11限制性乙型肝炎病毒HBc141-151表位肽的T细胞受体及其应用 | |
| CN113423724A (zh) | Ebv表位高亲和力t细胞受体 | |
| WO2018218878A1 (zh) | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 | |
| CN112940109B (zh) | 识别ebv抗原的t细胞受体及其应用 | |
| CN113122504A (zh) | 一种纯化ucart细胞的方法与应用 | |
| CN112469733B (zh) | Mart-1(27-35)表位特异性t细胞受体 | |
| CN113249331B (zh) | 负载Tax抗原的DC细胞、CTL细胞及其制备方法和应用 | |
| CN112538108B (zh) | 高亲和pvr突变体 | |
| CN111647606B (zh) | 靶向afp全抗原的dc细胞、ctl细胞及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |